Jonathan Milner, the Founder of Abcam plc, is an accomplished entrepreneur and investor dedicated to supporting UK life science and high-tech start-ups. He has invested in and provided mentorship to over 80 companies, playing a crucial role in facilitating three technology companies to achieve IPOs on the London AIM Stock exchange. Dr. Milner's expertise in molecular genetics, coupled with his research on breast cancer at the University of Cambridge, propelled him to establish Abcam, the world's leading supplier of antibody-based research reagents. Furthermore, he co-founded the Milner Centre for Evolution at the University of Bath and the Milner Institute for Therapeutics at the University of Cambridge, underscoring his active involvement in driving scientific initiatives. In addition, he holds a Non-Executive Director position at HealX, a company focused on discovering cures for rare childhood diseases. Among his various investments, Dr. Jonathan Milner also supported LIfT BioSciences, a socially-minded biotech start-up with a mission to develop immuno-oncology cell therapies for diverse solid tumor types. This effort holds the potential to offer improved scalability, efficacy, and safety.